Wision A.I. Expands U.S. Offerings to Combat CRC With Multiple Screening Tools (Globe Newswire)

SHANGHAI, March 22, 2022 (GLOBE NEWSWIRE) — Wision A.I. Ltd, a startup in the field of artificial intelligence assisted diagnostics for optical medical imaging, today announced the expansion of its product portfolio with recent U.S. Food & Drug Administration (FDA) 510(k) Clearance for EndoScreener, its AI-assisted polyp detection software during colonoscopy, and an FDA presubmission in queue for an upcoming histopathology AI software that assists in the localization of high-grade dysplasia (HGD) in whole slide imaging (WSI).